Compile Data Set for Download or QSAR
maximum 50k data
Found 987 with Last Name = 'aspnes' and Initial = 'ge'
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM2437(US8507533, 157)
Affinity DataKi:  5.55nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100827(US8507533, 138 | US8507533, 151 | US8507533, 374)
Affinity DataKi:  5.75nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100806(US8507533, 114 | US8507533, 115 | US8507533, 330)
Affinity DataKi:  7.60nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAtypical chemokine receptor 3(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50264278(CHEMBL4064803)
Affinity DataKi:  9nMAssay Description:Binding affinity to CXCR7 (unknown origin) assessed as inhibition constantMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM2390(US8507533, 146)
Affinity DataKi:  9.05nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50433595(CHEMBL2381827)
Affinity DataKi:  12nMAssay Description:Displacement of [125I]-glucagon-cex from human glucagon receptor by cell based assay in presence of 0.2% bovine serum albuminMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlucagon receptor(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50433577(CHEMBL2381848)
Affinity DataKi:  14nMAssay Description:Displacement of [125I]-glucagon-cex from human glucagon receptor by cell based assay in presence of 0.2% bovine serum albuminMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100806(US8507533, 114 | US8507533, 115 | US8507533, 330)
Affinity DataKi:  15.8nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100796(US8507533, 101)
Affinity DataKi:  17nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAtypical chemokine receptor 3(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50567153(CHEMBL4855707)
Affinity DataKi:  17nMAssay Description:Binding affinity to CXCR7 (unknown origin) assessed as inhibition constantMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100827(US8507533, 138 | US8507533, 151 | US8507533, 374)
Affinity DataKi:  20.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM2376(US8507533, 137)
Affinity DataKi:  20.2nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100844(US8507533, 160 | US8507533, 398)
Affinity DataKi:  25.7nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM2391(US8507533, 147)
Affinity DataKi:  26.7nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100850(US8507533, 168)
Affinity DataKi:  27.4nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100852(US8507533, 170 | US8507533, 419)
Affinity DataKi:  28nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100844(US8507533, 160 | US8507533, 398)
Affinity DataKi:  29nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100822(US8507533, 129 | US8507533, 162 | US8507533, 399)
Affinity DataKi:  29.3nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM2241(US8507533, 136)
Affinity DataKi:  30.2nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100838(US8507533, 153)
Affinity DataKi:  32.3nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM2240(US8507533, 135)
Affinity DataKi:  35nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100837(US8507533, 152)
Affinity DataKi:  35.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100805(US8507533, 113)
Affinity DataKi:  38.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAtypical chemokine receptor 3(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50567152(CHEMBL4877999)
Affinity DataKi:  40nMAssay Description:Binding affinity to CXCR7 (unknown origin) assessed as inhibition constantMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM2438(US8507533, 158)
Affinity DataKi:  41nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100861(US8507533, 188)
Affinity DataKi:  42.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100864(US8507533, 193)
Affinity DataKi:  44.7nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100815(US8507533, 122)
Affinity DataKi:  45.7nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAtypical chemokine receptor 3(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50264279(CHEMBL4072602)
Affinity DataKi:  47nMAssay Description:Binding affinity to CXCR7 (unknown origin) assessed as inhibition constantMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100822(US8507533, 129 | US8507533, 162 | US8507533, 399)
Affinity DataKi:  47.3nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM2229(US8507533, 187 | US8507533, 448)
Affinity DataKi:  47.8nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100824(US8507533, 131)
Affinity DataKi:  51nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAtypical chemokine receptor 3(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50567151(CHEMBL4848754)
Affinity DataKi:  52nMAssay Description:Binding affinity to CXCR7 (unknown origin) assessed as inhibition constantMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetAtypical chemokine receptor 3(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50567148(CHEMBL4875191)
Affinity DataKi:  53nMAssay Description:Binding affinity to CXCR7 (unknown origin) assessed as inhibition constantMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100801(US8507533, 109 | US8507533, 322)
Affinity DataKi:  57.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM2387(US8507533, 143)
Affinity DataKi:  57.4nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100826(US8507533, 133)
Affinity DataKi:  58nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100831(US8507533, 144)
Affinity DataKi:  62.6nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100829(US8507533, 140)
Affinity DataKi:  62.8nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50433576(CHEMBL2381849)
Affinity DataKi:  64nMAssay Description:Displacement of [125I]-glucagon-cex from human glucagon receptor by cell based assay in presence of 0.2% bovine serum albuminMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100847(US8507533, 163)
Affinity DataKi:  65.9nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100797(US8507533, 105)
Affinity DataKi:  69.8nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100799(US8507533, 107)
Affinity DataKi:  71.6nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100856(US8507533, 181)
Affinity DataKi:  87.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100816(US8507533, 123)
Affinity DataKi:  88.4nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100830(US8507533, 141)
Affinity DataKi:  89.5nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100798(US8507533, 106)
Affinity DataKi:  91.9nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100794(US8507533, 300 | US8507533, 97 | US8507533, 98)
Affinity DataKi:  93nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100823(US8507533, 130 | US8507533, 369)
Affinity DataKi:  93.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM2408(US8507533, 155)
Affinity DataKi:  94.9nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 987 total ) | Next | Last >>
Jump to: